Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel Klevebring is active.

Publication


Featured researches published by Daniel Klevebring.


Molecular Systems Biology | 2010

Defining the transcriptome and proteome in three functionally different human cell lines

Emma Lundberg; Linn Fagerberg; Daniel Klevebring; Ivan Matic; Tamar Geiger; Juergen Cox; Cajsa Älgenäs; Joakim Lundeberg; Matthias Mann; Mathias Uhlén

An essential question in human biology is how cells and tissues differ in gene and protein expression and how these differences delineate specific biological function. Here, we have performed a global analysis of both mRNA and protein levels based on sequence‐based transcriptome analysis (RNA‐seq), SILAC‐based mass spectrometry analysis and antibody‐based confocal microscopy. The study was performed in three functionally different human cell lines and based on the global analysis, we estimated the fractions of mRNA and protein that are cell specific or expressed at similar/different levels in the cell lines. A highly ubiquitous RNA expression was found with >60% of the gene products detected in all cells. The changes of mRNA and protein levels in the cell lines using SILAC and RNA ratios show high correlations, even though the genome‐wide dynamic range is substantially higher for the proteins as compared with the transcripts. Large general differences in abundance for proteins from various functional classes are observed and, in general, the cell‐type specific proteins are low abundant and highly enriched for cell‐surface proteins. Thus, this study shows a path to characterize the transcriptome and proteome in human cells from different origins.


European Urology | 2013

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.

Johan Lindberg; Daniel Klevebring; Wennuan Liu; Mårten Neiman; Jianfeng Xu; Peter Wiklund; Fredrik Wiklund; Ian G. Mills; Lars Egevad; Henrik Grönberg

BACKGROUND Prostate cancer (PCa) is a clinically and pathologically heterogeneous disease. The rapid development of sequencing technology has the potential to deliver new biomarkers with emphasis on aggressive disease and to revolutionise personalised cancer treatment. However, a prostate harbouring cancer commonly contains multiple separate tumour foci, with the potential to aggravate tumour sampling. The level of intraprostatic tumour heterogeneity remains to be determined. OBJECTIVE To determine the level of intraprostatic tumour heterogeneity through genome-wide, high-resolution profiling of multiple tumour samples from the same individual. DESIGN, SETTINGS, AND PARTICIPANTS Multiple tumour samples were obtained from four individuals following radical prostatectomy. One individual (SWE-1) contained >70% cancer cells in all tumour samples, whereas the other three (SWE-2 to SWE-4) required the use of laser capture microdissection for tumour cell enrichment. Subsequently, DNA was extracted from all tissue samples, and exome sequencing was performed. All tumour foci of SWE-1 were also profiled using a high-resolution array for the identification of copy number alterations (CNA). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Shared somatic high-frequency single nucleotide variants (SNV) and CNAs were used to infer the level of intraprostatic tumour heterogeneity. RESULTS AND LIMITATIONS No high-frequency mutations, common for the three tumour samples of SWE-1, were identified. Ten randomly chosen positions were validated with Sanger sequencing in all foci, which verified the exome data. The high level of intraprostatic heterogeneity was consistent in all individuals. In total, three out of four individuals harboured tumours without an apparent common somatic denominator. Although we cannot exclude the presence of common structural rearrangements, a high-density array was used for the detection of deletions and amplifications in SWE-1, which agreed with the exome data. CONCLUSIONS We present evidence for the presence of somatically independent tumours within the same prostate. This finding will have implications for personalised cancer treatment and biomarker discovery.


BMC Genomics | 2009

Genome-wide profiling of Populus small RNAs

Daniel Klevebring; Nathaniel R. Street; Noah Fahlgren; Krisitin D. Kasschau; James C. Carrington; Joakim Lundeberg; Stefan Jansson

BackgroundShort RNAs, and in particular microRNAs, are important regulators of gene expression both within defined regulatory pathways and at the epigenetic scale. We investigated the short RNA (sRNA) population (18-24 nt) of the transcriptome of green leaves from the sequenced Populus trichocarpa using a concatenation strategy in combination with 454 sequencing.ResultsThe most abundant size class of sRNAs were 24 nt. Long Terminal Repeats were particularly associated with 24 nt sRNAs. Additionally, some repetitive elements were associated with 22 nt sRNAs. We identified an sRNA hot-spot on chromosome 19, overlapping a region containing both the proposed sex-determining locus and a major cluster of NBS-LRR genes. A number of phased siRNA loci were identified, a subset of which are predicted to target PPR and NBS-LRR disease resistance genes, classes of genes that have been significantly expanded in Populus. Additional loci enriched for sRNA production were identified and characterised. We identified 15 novel predicted microRNAs (miRNAs), including miRNA*sequences, and identified a novel locus that may encode a dual miRNA or a miRNA and short interfering RNAs (siRNAs).ConclusionsThe short RNA population of P. trichocarpa is at least as complex as that of Arabidopsis thaliana. We provide a first genome-wide view of short RNA production for P. trichocarpa and identify new, non-conserved miRNAs.


PLOS ONE | 2010

Increased Throughput by Parallelization of Library Preparation for Massive Sequencing

Sverker Lundin; Henrik Stranneheim; Erik Pettersson; Daniel Klevebring; Joakim Lundeberg

Background Massively parallel sequencing systems continue to improve on data output, while leaving labor-intensive library preparations a potential bottleneck. Efforts are currently under way to relieve the crucial and time-consuming work to prepare DNA for high-throughput sequencing. Methodology/Principal Findings In this study, we demonstrate an automated parallel library preparation protocol using generic carboxylic acid-coated superparamagnetic beads and polyethylene glycol precipitation as a reproducible and flexible method for DNA fragment length separation. With this approach the library preparation for DNA sequencing can easily be adjusted to a desired fragment length. The automated protocol, here demonstrated using the GS FLX Titanium instrument, was compared to the standard manual library preparation, showing higher yield, throughput and great reproducibility. In addition, 12 libraries were prepared and uniquely tagged in parallel, and the distribution of sequence reads between these indexed samples could be improved using quantitative PCR-assisted pooling. Conclusions/Significance We present a novel automated procedure that makes it possible to prepare 36 indexed libraries per person and day, which can be increased to up to 96 libraries processed simultaneously. The yield, speed and robust performance of the protocol constitute a substantial improvement to present manual methods, without the need of extensive equipment investments. The described procedure enables a considerable efficiency increase for small to midsize sequencing centers.


European Urology | 2013

The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer

Johan Lindberg; Ian G. Mills; Daniel Klevebring; Wennuan Liu; Mårten Neiman; Jianfeng Xu; Pernilla Wikström; Peter Wiklund; Fredrik Wiklund; Lars Egevad; Henrik Grönberg

BACKGROUND Prostate cancer (PCa) is the most common cancer in men. PCa is strongly age associated; low death rates in surveillance cohorts call into question the widespread use of surgery, which leads to overtreatment and a reduction in quality of life. There is a great need to increase the understanding of tumor characteristics in the context of disease progression. OBJECTIVE To perform the first multigenome investigation of PCa through analysis of both autosomal and mitochondrial DNA, and to integrate exome sequencing data, and RNA sequencing and copy-number alteration (CNA) data to investigate how various different tumor characteristics, commonly analyzed separately, are interconnected. DESIGN, SETTING, AND PARTICIPANTS Exome sequencing was applied to 64 tumor samples from 55 PCa patients with varying stage and grade. Integrated analysis was performed on a core set of 50 tumors from which exome sequencing, CNA, and RNA sequencing data were available. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Genes, mutated at a significantly higher rate relative to a genomic background, were identified. In addition, mitochondrial and autosomal mutation rates were correlated to CNAs and proliferation, assessed as a cell cycle gene expression signature. RESULTS AND LIMITATIONS Genes not previously reported to be significantly mutated in PCa, such as cell division cycle 27 homolog (Saccharomyces cerevisiae) (CDC27), myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3), lysine (K)-specific demethylase 6A (KDM6A), and kinesin family member 5A (KIF5A) were identified. The mutation rate in the mitochondrial genome was 55 times higher than that of the autosomes. Multilevel analysis demonstrated a tight correlation between high reactive-oxygen exposure, chromosomal damage, high proliferation, and in parallel, a transition from multiclonal indolent primary PCa to monoclonal aggressive disease. As we only performed targeted sequence analysis; copy-number neutral rearrangements recently described for PCa were not accounted for. CONCLUSIONS The mitochondrial genome displays an elevated mutation rate compared to the autosomal chromosomes. By integrated analysis, we demonstrated that different tumor characteristics are interconnected, providing an increased understanding of PCa etiology.


Cell Reports | 2016

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis

Anna-Maria Georgoudaki; Kajsa E. Prokopec; Vanessa F. Boura; Eva Hellqvist; Silke Sohn; Jeanette Östling; Rony Dahan; Robert A. Harris; Mattias Rantalainen; Daniel Klevebring; Malin Sund; Suzanne Egyhazi Brage; Jonas Fuxe; Charlotte Rolny; Fubin Li; Jeffrey V. Ravetch; Mikael Karlsson

Tumors are composed of multiple cell types besides the tumor cells themselves, including innate immune cells such as macrophages. Tumor-associated macrophages (TAMs) are a heterogeneous population of myeloid cells present in the tumor microenvironment (TME). Here, they contribute to immunosuppression, enabling the establishment and persistence of solid tumors as well as metastatic dissemination. We have found that the pattern recognition scavenger receptor MARCO defines a subtype of suppressive TAMs and is linked to clinical outcome. An anti-MARCO monoclonal antibody was developed, which induces anti-tumor activity in breast and colon carcinoma, as well as in melanoma models through reprogramming TAM populations to a pro-inflammatory phenotype and increasing tumor immunogenicity. This anti-tumor activity is dependent on the inhibitory Fc-receptor, FcγRIIB, and also enhances the efficacy of checkpoint therapy. These results demonstrate that immunotherapies using antibodies designed to modify myeloid cells of the TME represent a promising mode of cancer treatment.


Journal of Proteome Research | 2013

Contribution of Antibody-based Protein Profiling to the Human Chromosome-centric Proteome Project (C-HPP)

Linn Fagerberg; Per Oksvold; Marie Skogs; Cajsa Älgenäs; Emma Lundberg; Fredrik Pontén; Åsa Sivertsson; Jacob Odeberg; Daniel Klevebring; Caroline Kampf; Anna Asplund; Evelina Sjöstedt; Cristina Al-Khalili Szigyarto; Per-Henrik Edqvist; IngMarie Olsson; Urban Rydberg; Paul Hudson; Jenny Ottosson Takanen; Holger Berling; Lisa Björling; Hanna Tegel; Johan Rockberg; Peter Nilsson; Sanjay Navani; Karin Jirström; Jan Mulder; Jochen M. Schwenk; Martin Zwahlen; Sophia Hober; Mattias Forsberg

A gene-centric Human Proteome Project has been proposed to characterize the human protein-coding genes in a chromosome-centered manner to understand human biology and disease. Here, we report on the protein evidence for all genes predicted from the genome sequence based on manual annotation from literature (UniProt), antibody-based profiling in cells, tissues and organs and analysis of the transcript profiles using next generation sequencing in human cell lines of different origins. We estimate that there is good evidence for protein existence for 69% (n = 13985) of the human protein-coding genes, while 23% have only evidence on the RNA level and 7% still lack experimental evidence. Analysis of the expression patterns shows few tissue-specific proteins and approximately half of the genes expressed in all the analyzed cells. The status for each gene with regards to protein evidence is visualized in a chromosome-centric manner as part of a new version of the Human Protein Atlas ( www.proteinatlas.org ).


Embo Molecular Medicine | 2013

CDK-mediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer

Diana Cepeda; Hwee-Fang Ng; Hamid Reza Sharifi; Salah Mahmoudi; Vanessa Soto Cerrato; Erik Fredlund; Kristina Magnusson; Helén Nilsson; Alena Malyukova; Juha Rantala; Daniel Klevebring; Francesc Viñals; Nimesh Bhaskaran; Siti Mariam Zakaria; Aldwin Suryo Rahmanto; Stefan Grotegut; Michael L. Nielsen; Cristina Al-Khalili Szigyarto; Dahui Sun; Mikael Lerner; Sanjay Navani; Martin Widschwendter; Mathias Uhlén; Karin Jirström; Fredrik Pontén; James A. Wohlschlegel; Dan Grandér; Charles H. Spruck; Lars-Gunnar Larsson; Olle Sangfelt

SCF (Skp1/Cul1/F‐box) ubiquitin ligases act as master regulators of cellular homeostasis by targeting key proteins for ubiquitylation. Here, we identified a hitherto uncharacterized F‐box protein, FBXO28 that controls MYC‐dependent transcription by non‐proteolytic ubiquitylation. SCFFBXO28 activity and stability are regulated during the cell cycle by CDK1/2‐mediated phosphorylation of FBXO28, which is required for its efficient ubiquitylation of MYC and downsteam enhancement of the MYC pathway. Depletion of FBXO28 or overexpression of an F‐box mutant unable to support MYC ubiquitylation results in an impairment of MYC‐driven transcription, transformation and tumourigenesis. Finally, in human breast cancer, high FBXO28 expression and phosphorylation are strong and independent predictors of poor outcome. In conclusion, our data suggest that SCFFBXO28 plays an important role in transmitting CDK activity to MYC function during the cell cycle, emphasizing the CDK‐FBXO28‐MYC axis as a potential molecular drug target in MYC‐driven cancers, including breast cancer.


Nature Genetics | 2016

Gene regulatory mechanisms underpinning prostate cancer susceptibility

Thomas Whitington; Ping Gao; Wei Song; Helen Ross-Adams; Alastair D. Lamb; Yuehong Yang; Ilaria Svezia; Daniel Klevebring; Ian G. Mills; Robert Karlsson; Silvia Halim; Mark J. Dunning; Lars Egevad; Anne Warren; David E. Neal; Henrik Grönberg; Johan Lindberg; Gong-Hong Wei; Fredrik Wiklund

Molecular characterization of genome-wide association study (GWAS) loci can uncover key genes and biological mechanisms underpinning complex traits and diseases. Here we present deep, high-throughput characterization of gene regulatory mechanisms underlying prostate cancer risk loci. Our methodology integrates data from 295 prostate cancer chromatin immunoprecipitation and sequencing experiments with genotype and gene expression data from 602 prostate tumor samples. The analysis identifies new gene regulatory mechanisms affected by risk locus SNPs, including widespread disruption of ternary androgen receptor (AR)-FOXA1 and AR-HOXB13 complexes and competitive binding mechanisms. We identify 57 expression quantitative trait loci at 35 risk loci, which we validate through analysis of allele-specific expression. We further validate predicted regulatory SNPs and target genes in prostate cancer cell line models. Finally, our integrated analysis can be accessed through an interactive visualization tool. This analysis elucidates how genome sequence variation affects disease predisposition via gene regulatory mechanisms and identifies relevant genes for downstream biomarker and drug development.


Breast Cancer Research | 2014

Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo

Daniel Klevebring; Gustaf Rosin; Ran Ma; Johan Lindberg; Kamila Czene; Juha Kere; Irma Fredriksson; Jonas Bergh; Johan Hartman

IntroductionThe cancer stem cell model implies a hierarchical organization within breast tumors maintained by cancer stem-like cells (CSCs). Accordingly, CSCs are a subpopulation of cancer cells with capacity for self-renewal, differentiation and tumor initiation. These cells can be isolated through the phenotypic markers CD44+/CD24-, expression of ALDH1 and an ability to form nonadherent, multicellular spheres in vitro. However, controversies to describe the stem cell model exist; it is unclear whether the tumorigenicity of CSCs in vivo is solely a proxy for a certain genotype. Moreover, in vivo evidence is lacking to fully define the reversibility of CSC differentiation.MethodsIn order to answer these questions, we undertook exome sequencing of CSCs from 12 breast cancer patients, along with paired primary tumor samples. As suggested by stem classical cell biology, we assumed that the number of mutations in the CSC subpopulation should be lower and distinct compared to the differentiated tumor cells with higher proliferation.ResultsOur analysis revealed that the majority of somatic mutations are shared between CSCs and bulk primary tumor, with similar frequencies in the two.ConclusionsThe data presented here exclude the possibility that CSCs are only a phenotypic consequence of certain somatic mutations, that is a distinct and non-reversible population of cells. In addition, our results imply that CSCs must be a population of cells that can dynamically switch from differentiated tumor cells, and vice versa. This finding increases our understanding of CSC function in tumor heterogeneity and the importance of identifying drugs to counter de-differentiation rather than targeting CSCs.

Collaboration


Dive into the Daniel Klevebring's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Per Hall

Karolinska Institutet

View shared research outputs
Top Co-Authors

Avatar

Joakim Lundeberg

Royal Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Emma Lundberg

Royal Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mathias Uhlén

Nova Southeastern University

View shared research outputs
Researchain Logo
Decentralizing Knowledge